The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1340
June 14, 2010
View Complete Issue         Table of Contents 2019 
A Plasma-derived Von Willebrand Factor/Factor VIII Concentrate (Wilate)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
A Plasma-derived Von Willebrand Factor/Factor VIII Concentrate (Wilate)
June 14, 2010 (Issue: 1340)
The FDA has approved a new plasma-derived von Willebrand factor/Factor VIII concentrate (Wilate – Octapharma) for treatment of spontaneous and trauma-induced bleeding episodes in patients with von Willebrand disease.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: A Plasma-derived Von Willebrand Factor/Factor VIII Concentrate (Wilate)
Article code: 1340b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.